NO985695L - Formulation and procedure for treating congestive heart attack - Google Patents

Formulation and procedure for treating congestive heart attack

Info

Publication number
NO985695L
NO985695L NO985695A NO985695A NO985695L NO 985695 L NO985695 L NO 985695L NO 985695 A NO985695 A NO 985695A NO 985695 A NO985695 A NO 985695A NO 985695 L NO985695 L NO 985695L
Authority
NO
Norway
Prior art keywords
congestive heart
formulation
heart attack
procedure
treating congestive
Prior art date
Application number
NO985695A
Other languages
Norwegian (no)
Other versions
NO985695D0 (en
Inventor
John L Mcnay
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO985695D0 publication Critical patent/NO985695D0/en
Publication of NO985695L publication Critical patent/NO985695L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Foreliggende oppfinnelse skaffer tilveie en fremgangsmåte for å behandle kongestiv hjerteinfarkt som består i å administrere en virksom mengde av 4-klor-5-(imidazolin-2- ylamino)-6-metoksy-2-metylpyrimidin i en oral eller implantert formulering med ikke umiddelbar frigjøring og formuleringer med ikke umiddelbar frigjøring.The present invention provides a method of treating congestive heart attack consisting of administering an effective amount of 4-chloro-5- (imidazolin-2-ylamino) -6-methoxy-2-methylpyrimidine in an oral or implanted formulation with non-immediate release and non-immediate release formulations.

NO985695A 1996-06-06 1998-12-04 Formulation and procedure for treating congestive heart attack NO985695L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65946396A 1996-06-06 1996-06-06
PCT/US1997/009914 WO1997046241A1 (en) 1996-06-06 1997-06-05 Formulation and method for treating congestive heart failure

Publications (2)

Publication Number Publication Date
NO985695D0 NO985695D0 (en) 1998-12-04
NO985695L true NO985695L (en) 1999-02-04

Family

ID=24645503

Family Applications (1)

Application Number Title Priority Date Filing Date
NO985695A NO985695L (en) 1996-06-06 1998-12-04 Formulation and procedure for treating congestive heart attack

Country Status (17)

Country Link
EP (1) EP0914128A1 (en)
JP (1) JP2000511906A (en)
KR (1) KR20000016406A (en)
CN (1) CN1226166A (en)
AU (1) AU3233197A (en)
BR (1) BR9709546A (en)
CA (1) CA2256720A1 (en)
CZ (1) CZ397698A3 (en)
EA (1) EA199900006A1 (en)
HU (1) HUP0003885A2 (en)
IL (1) IL126966A0 (en)
NO (1) NO985695L (en)
PL (1) PL330637A1 (en)
TR (1) TR199802496T2 (en)
WO (1) WO1997046241A1 (en)
YU (1) YU55998A (en)
ZA (1) ZA974978B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19815411A1 (en) * 1998-04-06 1999-10-07 Solvay Pharm Gmbh Thermogenesis stimulant comprising moxonidine, useful e.g. for treating hypothermia or promoting weight loss, having no cardiac stimulant side effects
AU2727400A (en) * 1999-01-29 2000-08-18 Eli Lilly And Company Moxonidine salts
UA67822C2 (en) * 1999-02-01 2004-07-15 Солвей Фармас'Ютікалс Гмбх Use of moxonidine for treatment of myocardial infarction damages of myocardium, method for producing pharmaceutical composition
ATE487712T1 (en) * 2006-08-31 2010-11-15 Chemagis Ltd USE OF MONOXIDINE SALTS TO PURIFY MONOXIDINE
KR100812287B1 (en) * 2007-01-03 2008-03-13 주식회사 챠콜코리아 Shade for a traffic signal lamp having reflective layer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4323570A (en) * 1978-11-15 1982-04-06 Beiersdorf Aktiengesellschaft Substituted aminopyrimidines
DE3617158C2 (en) * 1986-05-22 1994-10-06 Lohmann Therapie Syst Lts Transdermal drug
DE3729299A1 (en) * 1987-09-02 1989-03-23 Beiersdorf Ag TRANSDERMAL THERAPEUTIC SYSTEM
DE3904795C2 (en) * 1989-02-17 2000-10-12 Lilly Pharma Produktion Gmbh & Pharmaceutical preparation and its use
DE4325491A1 (en) * 1993-07-29 1995-02-02 Boehringer Ingelheim Kg Use of centrally acting alpha-2 agonists to inhibit post-aggression metabolism
DE4423177A1 (en) * 1994-07-01 1996-01-04 Kali Chemie Pharma Gmbh Antihyperglycemic drugs
CA2182851A1 (en) * 1995-08-15 1997-02-16 August Masaru Watanabe Method for treating substance abuse withdrawal

Also Published As

Publication number Publication date
TR199802496T2 (en) 1999-02-22
KR20000016406A (en) 2000-03-25
NO985695D0 (en) 1998-12-04
YU55998A (en) 1999-11-22
AU3233197A (en) 1998-01-05
BR9709546A (en) 1999-08-10
WO1997046241A1 (en) 1997-12-11
PL330637A1 (en) 1999-05-24
HUP0003885A2 (en) 2001-04-28
EA199900006A1 (en) 1999-06-24
IL126966A0 (en) 1999-09-22
EP0914128A1 (en) 1999-05-12
CN1226166A (en) 1999-08-18
CZ397698A3 (en) 1999-05-12
ZA974978B (en) 1998-12-07
CA2256720A1 (en) 1997-12-11
JP2000511906A (en) 2000-09-12

Similar Documents

Publication Publication Date Title
NO993979L (en) Procedures to prevent and delay the onset of Alzheimer's disease and its composition
TR199801315T2 (en) Use of a ppar-alpha and ppar-gamma antagonist for the treatment of syndrome X.
NO20012774D0 (en) Preparation and method using essential plant oils
ZA88798B (en) Dental anti-plaque and anti-caries agent
HU9603042D0 (en) Use of certain methanebisphosphonic acid derivatives to prevent or for treatment of prosthesis loosening and prosthesis migration
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
DE69814394D1 (en) USE OF LEVOBUPIVACAIN
MX9706957A (en) Composition containing amlodipine, or a salt or felodipine and anace inhibitor.
HK1047707A1 (en) Use of (+)-tramadol, o-demethyltramadol or (+)-o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol or (+)-o-desmethyl-n-mono-desmethyl-tramadol for treating urinary incontinence
TR199901003T2 (en) Composition containing loratadine and a decongestant for the treatment of asthma.
DE59308848D1 (en) USE OF URODILATIN IN LUNG AND BRONCHIAL DISEASES
FR2731907B1 (en) DEPIGMENTING DERMATOLOGICAL AND / OR COSMETIC COMPOSITION AND USE IN A COSMETIC METHOD
SE9603725D0 (en) New teatment
MX9703944A (en) Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis.
NO984760L (en) Use of an osmolyte in the treatment of effects caused by an infection, inflammation or immune dysfunction
NO985695L (en) Formulation and procedure for treating congestive heart attack
EP0744176A3 (en) Methods for inhibiting bone loss
UA50761C2 (en) Method for prevention and/or treatment of heart failure and ventricular dysfunction in warm-blooded animals, pharmaceutical formulation
DE69924483D1 (en) COMBINATION THERAPY FOR THE TREATMENT OF TUMORS
AU3439799A (en) Immunization against and treatment for infection by (h.pylori)
WO1999031136A3 (en) Methods for maintaining or restoring tissue-appropriate phenotype of soft tissue cells
EP0743068A3 (en) Composition for inhibiting bone loss containing vanadyl sulfate
HUP0104498A2 (en) Wood preservative formulations
AU6648200A (en) Method and composition for preventing or treating adverse physiological effects associated with cardiac disease
HUP9904578A2 (en) Use of xanomeline for the preparation of pharmaceutical compositions treating bipolar disorder

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application